Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
St Michael, Barbados
- Queen Elizabeth Hosp Respiratory Unit
-
-
-
-
California
-
Berkeley, California, United States, 94705
- East Bay AIDS Ctr
-
San Francisco, California, United States, 94109
- ViRx Inc
-
San Francisco, California, United States, 94118
- Kaiser Foundation Hospital
-
-
Colorado
-
Denver, Colorado, United States, 80204
- Infectious Disease and AIDS Clinic
-
-
District of Columbia
-
Washington, District of Columbia, United States, 200091104
- Dupont Circle Physicians Group
-
-
Florida
-
Jacksonville, Florida, United States, 32209
- Boulevard Comprehensive Care Ctr
-
Miami, Florida, United States, 33125
- Miami Veterans Administration Med Ctr
-
-
Illinois
-
Chicago, Illinois, United States, 60657
- TRIAD Health Practice
-
-
Indiana
-
Indianapolis, Indiana, United States, 46219
- Community Hosp Indianapolis
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Wayne State Univ / Harper Hosp
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- UMDNJ - New Jersey Med School / Cooper Hosp
-
Jersey City, New Jersey, United States, 07304
- Jersey City Med Ctr
-
-
New York
-
Brooklyn, New York, United States, 11203
- SUNY / Health Science Ctr at Brooklyn
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Univ of Pennsylvania School of Dental Medicine
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Med Univ of South Carolina
-
-
Texas
-
Dallas, Texas, United States, 75235
- Amelia Ct Clinic
-
San Antonio, Texas, United States, 78284
- Univ of Texas Health Sciences Ctr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
You may be eligible for this study if you:
- Are at least 18 years old.
- Are HIV-positive.
- Have thrush (oropharyngeal candidiasis).
- Agree to practice sexual abstinence or use effective barrier methods of birth control (e.g., condoms).
- Are able to take study medication and return for clinic visits during the study.
- Are expected to live for at least 2 months.
Exclusion Criteria
You will not be eligible for this study if you:
- Have received protease inhibitors for the first time within 30 days prior to study entry.
- Have received certain medications.
- Have certain other types of fungal infections.
- Have certain types of cancer.
- Have received SCH 56592 within 3 months prior to study entry.
- Are pregnant or breast-feeding.
- Cannot take medications by mouth.
- Are allergic to azole drugs.
- Have certain medical conditions.
- Have been in this study before.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: Double
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Stomatognathic Diseases
- Mouth Diseases
- Bacterial Infections and Mycoses
- Mycoses
- Candidiasis
- Candidiasis, Oral
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- 14-alpha Demethylase Inhibitors
- Trypanocidal Agents
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Posaconazole
- Fluconazole
Other Study ID Numbers
Other Study ID Numbers
- 305A
- C97-331
- I97-331
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.